000 05769nam a2200433 c 4500
710 2 _aSpringerLink (Online service)
_9106996
999 _c117822
_d117822
_x1
001 117822
003 ES-MaUEC
005 20230309093200.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 200130s2020 si a o |||| 0|eng d
020 _a9789813297050
024 7 _a10.1007/978-981-32-9705-0
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC531
_b2020 EB
245 0 0 _aAnxiety Disorders :
_bRethinking and Understanding Recent Discoveries
_cedited by Yong-Ku Kim
250 _aFirst edition
264 1 _aSingapore
_bSpringer International Publishing
_c2020
300 _a1 recurso en línea (VII, 576 páginas)
_b32 ilustraciones, 25 ilustraciones a color
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
490 0 _aAdvances in Experimental Medicine and Biology
_x0065-2598
_v1191
490 0 _aBiomedical and Life Sciences (Springer-11642)
505 0 _aPart 1. Brain network concepts -- Chapter 1. Task MRI-based functional brain network of anxiety -- Chapter 2. Phenotype network and brain structural covariance network of anxiety -- Chapter 3. linear/nonlinear micro-and-macro state EEG-based functional networks for anxiety -- Chapter 4. White matter-based structural brain network of anxiety -- Chapter 5. Resting state abnormalities in anxiety disorders and spatiotemporal psychopathology -- Part 2. Neurobiological Aspects -- Chapter 6. Gene-environmental interactions and role of epigenetics in anxiety disorders -- Chapter 7. The role of the oxytocin system in anxiety disorders -- Chapter 8. Translational studies in the complex roles of neurotransmitter systems in anxiety and anxiety disorders -- Chapter 9. The role of early life stress in HPA axis dysfunction in anxiety disorders -- Chapter 10. Immune-kynurenine pathways and the gut-microbiota-brain axis in anxiety disorders -- Chapter 11. Experimental anxiety model for anxiety disorders: relevance to drug discovery -- Part 3. Diagnostic and clinical Issues -- Chapter 12. Anxiety disorders in DSM-5: changes, controversies, and future directions -- Chapter 13. Biological markers to differentiate the type of anxiety disorders -- Chapter 14. Comorbid anxiety and depression: clinical and conceptual consideration, transdiagnostic treatment -- Chapter 15. Anxiety disorders and medical comorbidity: treatment implications -- Part 4. Therapeutic Issues -- Chapter 16. Biofeedback and Neurofeedback for Anxiety Disorders: A Quantitative and Qualitative Systematic Review -- Chapter 17. Cognitive Behavioral Therapy, Mindfulness-Based Cognitive Therapy and Acceptance Commitment Therapy for Anxiety Disorders: Integrating Traditional with Digital Treatment Approaches -- Chapter 18. Neurostimulation in anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder -- Chapter 19. Current and novel psychopharmacological drugs for anxiety disorders -- Chapter 20. Role of benzodiazepines in anxiety disorders -- Chapter 21. Virtual Reality for Anxiety Disorders: Rethinking a Field in Expansion -- Chapter 22. Current research on complementary and alternative medicine (CAM) in the treatments of anxiety disorders: evidence based review -- Chapter 23. Contemporary Psychodynamic Approaches to Treating Anxiety: Theory, Research, and Practice -- Chapter 24. Well-being therapy in anxiety disorders -- Part 5. Anxiety and precision psychiatry -- Chapter 25. Personalized clinical approaches to anxiety disorders -- Chapter 26. The role of hormonal and reproductive status in the treatment of anxiety disorders in women -- Chapter 27. Risk factors and prevention strategies for anxiety disorders in childhood and adolescence -- Chapter 28. Anxiety disorders in the elderly.
520 3 _aThis book reviews all important aspects of anxiety disorders with the aim of shedding new light on these disorders through combined understanding of traditional and novel paradigms. The book is divided into five sections, the first of which reinterprets anxiety from a network science perspective, examining the altered topological properties of brain networks in anxiety disorders. The second section discusses recent advances in understanding of the neurobiology of anxiety disorders, covering, for example, gene-environmental interactions and the roles of neurotransmitter systems and the oxytocin system. A wide range of diagnostic and clinical issues in anxiety disorders are then addressed, before turning attention to contemporary treatment approaches in the context of novel bio-psychosocial-behavioral models, including bio- and neurofeedback, cognitive behavioral therapy, neurostimulation, virtual reality exposure therapy, pharmacological interventions, psychodynamic therapy, and CAM options. The final section is devoted to precision psychiatry in anxiety disorders, an increasingly important area as we move toward personalized treatment. Anxiety Disorders will be of interest for all researchers and clinicians in the field.
988 _aPrimersemestre_2020_BiomedLife
650 7 _aEmociones y sentimientos
_2embne
_9413090
700 1 _aKim, Yong-Ku
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9789813297043
776 0 8 _iPrinted edition:
_z9789813297067
776 0 8 _iPrinted edition:
_z9789813297074
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-32-9705-0
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
_n0
998 _b03/2020
_dz
_ek
_zSI